Navigation Links
AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
Date:1/28/2009

AMSTERDAM, The Netherlands, January 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today during the Phacilitate Cell & Gene Therapy Forum new data showing that one treatment of its lead product Glybera(R) results in a long term significant and clinically important lowering of the incidence of acute pancreatitis in Lipoprotein Lipase Deficient patients. Recurrent acute pancreatitis is the most debilitating complication of Lipoprotein Lipase Deficiency (LPLD) and is associated with significant morbidity and mortality.

To date only one patient from the two clinical trials had an acute pancreatitis during the long-term follow-up, while seven episodes of pancreatitis would have been expected based on the observational studies in the same patients. This equals a lowering of the incidence of pancreatitis from 0.33 per patient per year to 0.05 for both trials. The data were obtained from two observational and two interventional clinical studies with 22 patients and follow up data from 1 to 3.5 years after the treatment. The studies result in a total of more than 38 patient years worth of data.

Other positive effects of Glybera are the disappearance or reduction of fat accumulations in the skin or retina. The data also confirm that the treatment is well-tolerated and safe.

AMT has developed Glybera as an effective treatment for patients with the rare genetic disorder LPLD. Because of a defective gene, LPLD patients do not produce an enzyme that normally breaks down a certain type of fat carrying particles in the blood. Glybera is a gene therapy, which restores the enzyme (lipoprotein lipase) activity required to process the fat carrying particles. LPLD patients have extremely high fat levels in their blood, resulting in recurrent and potentially lethal pancreatitis as well as an increased risk of cardiovascula
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
2. AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Kmart Lowers Flu Shot Price to $10
7. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
8. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
9. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
10. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
11. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... FAIRFIELD, N.J. , Oct. 22, 2014 /PRNewswire/ ... a major transformation in the pain market, according ... Pain Insights, Inc., a firm providing market research ... management. Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... a scheduling change for hydrocodone combination products from ...
(Date:10/22/2014)... Vernak, RPh, of Vernak Farms Pharmacy in ... George Roentsch Scholarship by the Professional Compounding Centers of ... Houston during PCCA,s International Seminar, held October ... independent pharmacist and PCCA member who embodies the innovative ... well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... Calif., May 27 Epeius Biotechnologies,( http://www.epeiusbiotech.com ) ... Feasibility Study of sequential targeted gene delivery -- ... will be presented at the,ASCO meetings in Chicago ... 2008).,Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles,bearing a ...
... in high risk node-negative, population to show ... BRIDGEWATER, N.J., May 27 Sanofi-aventis ... de Mama) announced today,that for women with ... (post surgery) with Taxotere(R) (docetaxel) Injection,Concentrate as ...
Cached Medicine Technology:TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 2TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008) 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 2Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 3Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 4Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy 5
(Date:10/22/2014)... (PRWEB) October 22, 2014 On October ... Minds featuring skin diseases both fictional and real. ... (CEHMDF), a nonprofit organization committed to advocacy and philanthropy ... CBS will take the opportunity to impart truth and ... , There are many misconceptions about Morgellons ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... a recent study researchers find people who get only four hours ... turn could lead to weight gain. ,An investigation was ... were measured before the study started, after they had slept about ... slept about 10 hours a night for two nights. Levels of ...
... of the existing drugs on the market are losing ... soil bacteria hence researchers feel that the ocean is ... ,More than 1 million microorganisms fill every milliliter ... treatment for some of our deadliest diseases. Many marine ...
... God willing, in about a month’s time from now five-year-old ... return home to Baghdad as normal children.// Part of a ... to surgically correct their complicated cardiac problems by the Much ... babies, these two underwent assessment this evening by a paediatric ...
... Parkinson’s disease is a neurological condition that can cause slowness ... // both of these problems say researchers. A pulse of ... movement. This is done inorder to improve stiffness in patients. ... magnetic stimulation. ,For nearly 15 years, Criner has dealt ...
... risks and benefits of using CT scanning for young ... more than 3,000 men who received radiation therapy before ... tested at age 18 years or 19 years. Researchers ... ,Results of the study showed boys who received ...
... Reports suggest as many as 14 percent of pregnant ... of women use antidepressants during pregnancy. Studies involving infants ... shown few ill effects, so most doctors believe these ... most studies have only compared major outcomes, such as ...
Cached Medicine News:
... SES ("SES") is a surgical/ mechanical device ... layer of the cornea above Bowman's layer. ... alcohol currently used during LASEK to delaminate ... alcohol and providing a 'minimal-touch' surgical approach, ...
... You told us you wanted a ... installations and a lightweight portable for mobile ... XLTEK listened, and we answered with Protektor, our leading-edge, ... Both configurations feature XLTEK’s ruggedness, ...
... Creating more efficiency for high volume laboratories, ... extended walk away time. This high-speed analyzer ... to 1600 photometric test results per hour ... up to 51 tests on-board. Consolidate with ...
... size fits all plug. Once inserted into the punctum, ... it hydrates, Form Fit increases in size until it ... perfect fit. ,The Form Fit plug is made ... pliable, gelatinous material when it contacts tear film. The ...
Medicine Products: